Logo image of TLSI

TRISALUS LIFE SCIENCES INC (TLSI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TLSI - US89680M1018 - Common Stock

5.87 USD
+0.07 (+1.21%)
Last: 1/12/2026, 8:00:01 PM
5.87 USD
0 (0%)
After Hours: 1/12/2026, 8:00:01 PM
Fundamental Rating

2

Overall TLSI gets a fundamental rating of 2 out of 10. We evaluated TLSI against 528 industry peers in the Biotechnology industry. TLSI may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, TLSI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TLSI had negative earnings in the past year.
In the past year TLSI has reported a negative cash flow from operations.
In multiple years TLSI reported negative net income over the last 5 years.
In the past 5 years TLSI always reported negative operating cash flow.
TLSI Yearly Net Income VS EBIT VS OCF VS FCFTLSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

The Return On Assets of TLSI (-198.16%) is worse than 87.69% of its industry peers.
Industry RankSector Rank
ROA -198.16%
ROE N/A
ROIC N/A
ROA(3y)-123.26%
ROA(5y)-73.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TLSI Yearly ROA, ROE, ROICTLSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

Looking at the Gross Margin, with a value of 84.04%, TLSI belongs to the top of the industry, outperforming 86.74% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for TLSI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLSI Yearly Profit, Operating, Gross MarginsTLSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

TLSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLSI has been increased compared to 1 year ago.
The debt/assets ratio for TLSI is higher compared to a year ago.
TLSI Yearly Shares OutstandingTLSI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
TLSI Yearly Total Debt VS Total AssetsTLSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

TLSI has an Altman-Z score of -10.56. This is a bad value and indicates that TLSI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TLSI (-10.56) is worse than 73.30% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.56
ROIC/WACCN/A
WACC8.64%
TLSI Yearly LT Debt VS Equity VS FCFTLSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

TLSI has a Current Ratio of 3.05. This indicates that TLSI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.05, TLSI is doing worse than 63.45% of the companies in the same industry.
TLSI has a Quick Ratio of 2.75. This indicates that TLSI is financially healthy and has no problem in meeting its short term obligations.
TLSI's Quick ratio of 2.75 is on the low side compared to the rest of the industry. TLSI is outperformed by 65.34% of its industry peers.
Industry RankSector Rank
Current Ratio 3.05
Quick Ratio 2.75
TLSI Yearly Current Assets VS Current LiabilitesTLSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

5

3. Growth

3.1 Past

TLSI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.39%, which is quite impressive.
TLSI shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.57%.
EPS 1Y (TTM)47.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.33%
Revenue 1Y (TTM)20.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%57.38%

3.2 Future

Based on estimates for the next years, TLSI will show a very strong growth in Earnings Per Share. The EPS will grow by 28.83% on average per year.
TLSI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.95% yearly.
EPS Next Y-22.96%
EPS Next 2Y35.42%
EPS Next 3Y28.83%
EPS Next 5YN/A
Revenue Next Year52.85%
Revenue Next 2Y49.4%
Revenue Next 3Y46.42%
Revenue Next 5Y38.95%

3.3 Evolution

TLSI Yearly Revenue VS EstimatesTLSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
TLSI Yearly EPS VS EstimatesTLSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TLSI. In the last year negative earnings were reported.
Also next year TLSI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLSI Price Earnings VS Forward Price EarningsTLSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLSI Per share dataTLSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

TLSI's earnings are expected to grow with 28.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.42%
EPS Next 3Y28.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TLSI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TRISALUS LIFE SCIENCES INC

NASDAQ:TLSI (1/12/2026, 8:00:01 PM)

After market: 5.87 0 (0%)

5.87

+0.07 (+1.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-24 2026-03-24/bmo
Inst Owners19.32%
Inst Owner Change0%
Ins Owners18.04%
Ins Owner Change9.05%
Market Cap293.27M
Revenue(TTM)40.21M
Net Income(TTM)-72.25M
Analysts83.08
Price Target11.58 (97.27%)
Short Float %2.83%
Short Ratio4.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-43.04%
Min EPS beat(2)-64.97%
Max EPS beat(2)-21.11%
EPS beat(4)0
Avg EPS beat(4)-45.86%
Min EPS beat(4)-73.8%
Max EPS beat(4)-21.11%
EPS beat(8)3
Avg EPS beat(8)-21.42%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.38%
Min Revenue beat(2)-3.58%
Max Revenue beat(2)2.81%
Revenue beat(4)1
Avg Revenue beat(4)-0.37%
Min Revenue beat(4)-3.58%
Max Revenue beat(4)2.81%
Revenue beat(8)4
Avg Revenue beat(8)0.75%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.24%
EPS NQ rev (1m)-0.88%
EPS NQ rev (3m)-19.48%
EPS NY rev (1m)-1.86%
EPS NY rev (3m)-94.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.29
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.31
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.8
BVpS-0.53
TBVpS-0.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -198.16%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.04%
FCFM N/A
ROA(3y)-123.26%
ROA(5y)-73.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.1
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 132.85%
Cap/Sales 2.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.05
Quick Ratio 2.75
Altman-Z -10.56
F-Score3
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.33%
EPS Next Y-22.96%
EPS Next 2Y35.42%
EPS Next 3Y28.83%
EPS Next 5YN/A
Revenue 1Y (TTM)20.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%57.38%
Revenue Next Year52.85%
Revenue Next 2Y49.4%
Revenue Next 3Y46.42%
Revenue Next 5Y38.95%
EBIT growth 1Y26.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.68%
EBIT Next 3Y28.55%
EBIT Next 5Y21.3%
FCF growth 1Y47.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.68%
OCF growth 3YN/A
OCF growth 5YN/A

TRISALUS LIFE SCIENCES INC / TLSI FAQ

What is the fundamental rating for TLSI stock?

ChartMill assigns a fundamental rating of 2 / 10 to TLSI.


What is the valuation status of TRISALUS LIFE SCIENCES INC (TLSI) stock?

ChartMill assigns a valuation rating of 1 / 10 to TRISALUS LIFE SCIENCES INC (TLSI). This can be considered as Overvalued.


What is the profitability of TLSI stock?

TRISALUS LIFE SCIENCES INC (TLSI) has a profitability rating of 1 / 10.


What is the earnings growth outlook for TRISALUS LIFE SCIENCES INC?

The Earnings per Share (EPS) of TRISALUS LIFE SCIENCES INC (TLSI) is expected to decline by -22.96% in the next year.